Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD
May 16 2018 - 1:36PM
Business Wire
Results from MAKO Study to be used to help
design and simulate clinical trials in wAMD
Vitrisa Therapeutics, Inc., a Company focused on developing a
suite of platform technologies optimized for ocular therapeutics
and an associated pipeline of therapeutics in sight-threatening
ocular diseases, today announced that it has entered into an option
agreement with Ohr Pharmaceutical for certain rights to the data
from the MAKO study in wet-AMD (“wAMD”). Under the terms of the
newly announced deal, Vitrisa will initially receive non-exclusive
rights to the data and a time-limited option to acquire worldwide
exclusive ownership of the MAKO clinical trial database.
The MAKO study was a 237 patient, multi-center, randomized,
double-masked, placebo-controlled clinical trial to evaluate the
efficacy and safety of squalamine and Lucentis combination therapy
vs. Lucentis monotherapy for the treatment of wAMD. Ohr reported in
January 2018 that the study did not meet its primary endpoint.
Vitrisa is acquiring the clinical database in order to use the
clinical data set to run virtual clinical trials and evaluate
innovative clinical strategies in wAMD.
“We are excited to gain access to the rigorously collected data
from the MAKO study in order to better inform our clinical strategy
for our programs in wAMD,” said Carl Erickson, CEO of Vitrisa.
“Despite not meeting the primary endpoint, the MAKO study was a
well-designed and run study in wAMD that included a gold standard
anti-VEGF monotherapy arm. With access to the clinical database, we
will be able to de-risk our programs through virtual clinical
trials using the Lucentis monotherapy arm and simulated treatment
effects based on our programs in wAMD. In addition, we are pleased
to be able to have the option to share the results of our
sub-analyses of the MAKO study with the retina community at future
scientific meetings.”
Through an upfront payment, Vitrisa will gain initial
non-exclusive access to summary data for the Lucentis monotherapy
arm in the MAKO study and the option to acquire worldwide exclusive
ownership of the entire clinical database for a period of 90 days
following initial access. Specific financial details of the deal
were not disclosed.
Vitrisa Therapeutics, Inc. is privately held and
venture-backed biotechnology company based in the San Francisco Bay
Area. Vitrisa is focused on developing a suite of platform
technologies optimized for ocular therapeutics and an associated
pipeline of therapeutics to address significant unmet medical needs
in sight-threatening ocular diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180516006204/en/
Vitrisa Therapeutics, Inc.Catherine
MullerIR@vitrisatherapeutics.com